Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558759 | 0.82 | ALDH1A1 (0.71) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL2627222 | 0.81 | FGFR1 (0.53) | ALDH1A1KDM4ECYP3A4POLBCYP2E1 | |
| SCHEMBL9402020 | 0.80 | KMT2A (0.45) | ALDH1A1NOS1HTTCYP1A2CYP19A1 | |
| SCHEMBL17743745 | 0.80 | MEN1 (0.45) | ALDH1A1NOS1HTTCYP1A2CYP19A1 | |
| SCHEMBL5390679 | 0.80 | MAPT (0.47) | ALDH1A1NOS1HTTCYP1A2MAPT | |
| SCHEMBL7557950 | 0.80 | MEN1 (0.45) | ALDH1A1NOS1HTTCYP1A2CYP19A1 | |
| SCHEMBL9615636 | 0.80 | KMT2A (0.48) | ALDH1A1NOS1HTTCYP1A2POLB | |
| SCHEMBL14909623 | 0.80 | MAPT (0.51) | ALDH1A1NOS1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL17743800 | 0.78 | SMN1; SMN2 (0.55) | ALDH1A1HTTKDM4ECYP3A4CYP1A2 | |
| SCHEMBL4324562 | 0.78 | MAPK9 (0.52) | NOS1HTTCYP1A2CYP19A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579320-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-10-22 | — | — | US | disclosed |
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-10-22 | — | — | US | disclosed |
| EP-2323993-B1 | 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARM INC (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8952027-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952027-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8859611-B2 | Thiophene inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2512247-B1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20140057957-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8586624-B2 | Thiophene inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-5231182-A | Platelet activating factor inhibitor | AMERICAN CYANAMID COMPANY (US) | 1993-07-27 | — | — | US | disclosed |
| US-5225425-A | Respiratory system disorders | AMERICAN CYANAMID COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0497512-A2 | Imidazole, triazole and tetrazole derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-08-05 | — | — | EP | disclosed |
| US-5128351-A | BIS-ARYL AMIDE AND UREA ANTAGONISTS OF PLATELET ACTIVATING FACTOR | AMERICAN CYANAMID COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| US-5077409-A | Reducing hydroxy bis-aryl amide, acylating, hydrolyzing, sulfonating, halogenating, alkylating with nitrogen heterocycle | AMERICAN CYANAMID COMPANY (US) | 1991-12-31 | — | — | US | disclosed |
| EP-0458037-A1 | Bis-aryl amide and urea antagonists of platelet activating factor | AMERICAN CYANAMID COMPANY (US) | 1991-11-27 | — | — | EP | disclosed |
| US-4602031-A | Anti-depressant imidazoles, compositions and use | EISAI CO., LTD. (JP) | 1986-07-22 | — | — | US | disclosed |
| US-4533669-A | NONTOXIC | EISAI CO., LTD. (JP) | 1985-08-06 | — | — | US | disclosed |
| US-4402966-A | Acylaminophenyl imidazoles and anti-depressing agent containing the same | EISAI CO., LTD. (JP) | 1983-09-06 | — | — | US | disclosed |
| US-4301169-A | Novel imidazole compound and anti-depressing agent containing the same | EISAI CO., LTD. (JP) | 1981-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | ALDH1A1 3700/4885NOS1 628/4885HTT 1377/4885 |
| US-20140057957-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | ALDH1A1 346/4885NOS1 77/4885HTT 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.